rosiglitazone has been researched along with insulin glargine in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dailey, G; Rosenstock, J; Soltes-Rak, E; Stewart, JA; Strange, P; Sugimoto, D | 1 |
| Hamid, Z; Simmons, DL | 1 |
| Cersosimo, E; De Filippis, E; DeFronzo, RA; Gastaldelli, A; Glass, L; Miyazaki, Y; Triplitt, C; Wajcberg, E | 1 |
| Karounos, DG; Kingsley, FJ; Reynolds, LR; Tannock, LR | 1 |
| Vinik, AI; Zhang, Q | 1 |
| Alagona, C; Chiavetta, A; Fedele, V; Leotta, C; Lorenti, I; Luca, S; Papa, G; Pezzino, V; Piro, S; Purrello, F; Rabuazzo, AM; Spadaro, L | 1 |
| Brath, H; Ludvik, B; Toplak, H; Wascher, T | 1 |
| Chaudhuri, A; Dandona, P; DiGenio, A; Hollander, P; Ilgenfritz, J; McGill, JB; Meneghini, L; Riddle, M; Rosenstock, J | 1 |
| Nauck, MA | 1 |
| Andreeff, M; Benito, JM; Chen, C; Fuentes-Mattei, E; Jin, Y; Konopleva, M; Lee, MH; Pan, J; Velazquez-Tores, G; Yeung, SC | 1 |
| Bøgelund, M; Ericsson, Å; Jendle, J; Nilsen, B; Ridderstråle, M; Torffvit, O | 1 |
| Ravid, M | 1 |
1 review(s) available for rosiglitazone and insulin glargine
| Article | Year |
|---|---|
The design of the liraglutide clinical trial programme.
Topics: Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2012 |
6 trial(s) available for rosiglitazone and insulin glargine
| Article | Year |
|---|---|
Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Lipids; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2006 |
Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
Topics: Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liver; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2006 |
Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes.
Topics: Biomarkers; Blood Glucose; C-Reactive Protein; Cholesterol; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Insulin; Insulin Glargine; Insulin, Long-Acting; Lipids; Plasminogen Activator Inhibitor 1; Rosiglitazone; Thiazolidinediones; Triglycerides | 2007 |
Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes.
Topics: Adult; Aged; Body Mass Index; Diabetes Mellitus, Type 2; Female; Health Status; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Middle Aged; Psychometrics; Quality of Life; Rosiglitazone; Surveys and Questionnaires; Thiazolidinediones | 2007 |
Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs.
Topics: Administration, Oral; Aged; Blood Glucose; Body Mass Index; Carbamates; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Pioglitazone; Piperidines; Research Design; Rosiglitazone; Thiazolidinediones | 2008 |
Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Male; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2012 |
5 other study(ies) available for rosiglitazone and insulin glargine
| Article | Year |
|---|---|
Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients: response to Rosenstock et al.
Topics: Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2006 |
[The significance of long acting insulin analogues in the treatment of type 2 diabetes mellitus].
Topics: Austria; Body Weight; Cohort Studies; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Detemir; Insulin Glargine; Insulin, Long-Acting; Myocardial Infarction; Practice Guidelines as Topic; Quality of Life; Randomized Controlled Trials as Topic; Retrospective Studies; Rosiglitazone; Thiazolidinediones | 2009 |
Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells.
Topics: Adolescent; Apoptosis; Cell Line, Tumor; Cell Proliferation; Child; Child, Preschool; Daunorubicin; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Aspart; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-akt; Rosiglitazone; Thiazolidinediones; TOR Serine-Threonine Kinases | 2012 |
Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
Topics: Cost of Illness; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Disease Management; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Peptides; Randomized Controlled Trials as Topic; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Venoms; Weight Loss | 2012 |
Carcinophobia in clinical research.
Topics: Angiotensin Receptor Antagonists; Animals; Biomedical Research; Causality; Clopidogrel; Cyclooxygenase 2 Inhibitors; Humans; Incidence; Insulin Glargine; Insulin, Long-Acting; Neoplasms; Rosiglitazone; Thiazolidinediones; Ticlopidine | 2012 |